Skip to content
🌐 Global🇮🇳 India📍 Asia-Pacific📍 Bihar📍 Delhi-NCR📍 East India📍 Europe📍 Gujarat📍 Karnataka📍 Kerala📍 Madhya Pradesh📍 Maharashtra📍 Middle East📍 North India📍 Northeast India📍 Punjab📍 Rajasthan📍 South India📍 Tamil Nadu📍 Telangana📍 United Kingdom📍 United States📍 Uttar Pradesh📍 West Bengal📍 West India
LIVE
Home / Business
Business

Piramal Pharma to acquire remaining 26% stake in Yapan Bio

Piramal Pharma announced that it will acquire the remaining 26 percent stake in Yapan Bio, giving it full ownership of the company. The deal will integrate Yapan Bio’s large molecule expertise into Piramal’s service platform.

The Hindu BusinessNovember 19, 20261 min read
Share this story
Piramal Pharma to acquire remaining 26% stake in Yapan Bio
The Strategic Consequence
Monitor how the merged company positions its services in upcoming biotech conferences and client announcements.

Piramal Pharma, a major player in the Indian contract development and manufacturing sector, has moved to complete its purchase of Yapan Bio, a biotech firm known for its work on complex protein‑based medicines. The transaction, valued at several hundred million rupees, will give Piramal 100 percent control over Yapan Bio’s assets, research facilities and client contracts. This step follows an earlier agreement in which Piramal bought a 74 percent share, leaving the remaining portion under the control of Yapan’s founders.

Yapan Bio’s capabilities in large molecule development include cell culture, purification and analytical services that are essential for the production of biologics such as monoclonal antibodies and therapeutic enzymes. By bringing these services under one roof, Piramal aims to offer end‑to‑end solutions to pharmaceutical companies that are increasingly looking for partners who can handle both small and large molecule projects. Industry analysts note that the move could help Piramal attract new business from global firms seeking to outsource complex biologics work.

Advertisement

For Indian biotech and pharmaceutical firms, the acquisition signals a growing confidence in the country’s ability to support advanced drug development. It may also encourage further investment in research infrastructure and talent development, as companies look to expand their service portfolios. Observers expect that the combined entity will focus on expanding its client base in North America and Europe while strengthening its presence in the domestic market.

📡 Verified Wire Agency Verified Resource & Provenance
✉
The Next Brief
Get the day's most important stories in one email
AI-curated morning digest. No noise. Unsubscribe anytime.

Comments 0

Advertisement

Related stories

Most read

  1. 1Tech Glitches Disrupt United Airlines and Major U.S. BanksTechnology
  2. 2Unclaimed Wealth Liquidation and the Supreme Court Battle Over Inherited AssetsFinance
  3. 3Karnataka Unveils Advanced Tech Blueprint to Accelerate Artificial Intelligence and Deep TechTechnology
  4. 4Nvidia Places Megaspeed on No‑Sell List Amid US ProbeTechnology
  5. 5Washington Tightens Export Controls on AI Hardware After Nvidia FalloutTechnology